Clinical Trials

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06351332 2026-05-22

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Phase 1/2 Terminated

7 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06954480 2026-05-22

DIAMOND

140 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06963905 2026-05-22

SIMONE

60 enrolled

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT07597642 2026-05-22

ONSET

55 enrolled

Triple Negative Breast Neoplasms

NCT07601178 2026-05-22

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

34 enrolled

Triple Negative Breast Neoplasms

NCT06246968 2026-05-20

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Phase 1 Recruiting

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07011654 2026-05-20

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

31 enrolled

Triple Negative Breast Neoplasms

NCT07340541 2026-05-20

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Recruiting

20 enrolled

Triple Negative Breast Neoplasms

NCT05115474 2026-05-18

Study of Screening Brain MRIs in Stage IV Breast Cancer

170 enrolled

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06618014 2026-05-15

NeoTOP

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07394387 2026-05-15

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

58 enrolled

Phase EARLY_PHASE1 Recruiting

Triple Negative Breast Neoplasms

NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

15 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07283692 2026-05-13

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

46 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03941730 2026-05-12

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

8 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04348747 2026-05-11

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 1 Active not recruiting

23 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT05809752 2026-05-11

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

15 enrolled

Phase 2 Active not recruiting

Meningeal Neoplasms, Triple Negative Breast Neoplasms

NCT05498896 2026-05-08

BARBICAN

146 enrolled

Triple Negative Breast Neoplasms

NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

168 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06380816 2026-05-08

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

BreastGastrointestinalGynecologicHead & NeckThoracic

167 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04771871 2026-05-07

TARMAC

42 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 3 Active not recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02488967 2026-05-06

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

782 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04331067 2026-05-06

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

15 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

34 enrolled

Triple Negative Breast Neoplasms

NCT06845319 2026-05-06

NeoCARD

43 enrolled

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07178730 2026-05-06

ADAPT-TN-IV

765 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07552181 2026-05-06

Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer

50 enrolled